OnKure Therapeutics (NASDAQ:OKUR - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for OnKure Therapeutics in a research report issued on Thursday, October 17th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($1.12) per share for the quarter. HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for OnKure Therapeutics' current full-year earnings is ($1.62) per share. HC Wainwright also issued estimates for OnKure Therapeutics' Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.19) EPS and Q4 2025 earnings at ($1.21) EPS.
OKUR has been the subject of a number of other research reports. Oppenheimer began coverage on OnKure Therapeutics in a research note on Thursday, October 10th. They issued an "outperform" rating and a $35.00 price objective for the company. Lifesci Capital upgraded OnKure Therapeutics to a "strong-buy" rating in a report on Thursday, October 10th.
Get Our Latest Stock Report on OnKure Therapeutics
Shares of OnKure Therapeutics stock opened at $17.95 on Friday. OnKure Therapeutics has a 52 week low of $9.80 and a 52 week high of $86.70. The company has a market capitalization of $59.95 million, a price-to-earnings ratio of -1.07 and a beta of 0.21.
Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider OnKure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OnKure Therapeutics wasn't on the list.
While OnKure Therapeutics currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.